RxDoctor Payments Data

Arthur Autz, MD

Podiatrist · Huntington, NYNPI 1881612935

Payments from drug & device makers

$1,504in general payments, 2019–2025

Across 43 payments — averaging $34.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$723
  • Novartis$245
  • Merck$138
  • Amgen$99
  • Novo Nordisk$82
  • Amarin Pharma, Inc.$74
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$1,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,504 in reported general payments places this provider in the 65th percentile of 862 podiatrist providers in New York.

See all podiatrist providers in New York

Medicare billing

Part B allowed, 2024
$67,571
Medicare patients
71
Services billed
893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$33,462
JanumetSitagliptin Phos/Metformin Hcl13$12,859
Rosuvastatin Calcium94$1,006
Atorvastatin Calcium126$604
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide21$566
Metoprolol Succinate20$529
Levothyroxine Sodium42$477
Omeprazole53$439
Atenolol32$402
Albuterol Sulfate HfaAlbuterol Sulfate18$394
Alprazolam35$386
Levocetirizine Dihydrochloride16$371
Enalapril Maleate41$364
Enalapril-HydrochlorothiazideEnalapril/Hydrochlorothiazide14$354
Metformin Hcl69$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$82$33,46218 claims
MerckJanumet$138$12,85913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 862 podiatrist providers in New York.

Other podiatrist in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →